The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Jean-Marc Nabholtz

Breast Cancer Research Institute

La Prandie

24290 Valojoulx



Name/email consistency: high



  • Breast Cancer Research Institute, La Prandie, 24290 Valojoulx, France. 2005 - 2008
  • University of California at Los Angeles, CA 90095-7077, USA. 2003
  • Cancer Therapy Development Program, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, USA. 2003
  • University of California at Los Angeles, Suite 3360B, Peter Ueberroth Bldg, 10945 Leconte Avenue, USA. 2003
  • Department of Medicine, Division of Medical Oncology, American Hospital of Paris, and Hartmann Clinic, France. 2003
  • American Hospital of Paris, 63, Boulevard Victor Hugo, 92200 Neuilly s/Seine, France. 2003


  1. Aromatase inhibitors in the management of early breast cancer. Nabholtz, J.M. Eur. J. Surg. Oncol (2008) [Pubmed]
  2. The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. Nabholtz, J.M., Gligorov, J. Rev. Recent. Clin. Trials (2006) [Pubmed]
  3. Taxane therapy for early stage breast cancer. Nabholtz, J.M., Gligorov, J. Womens. Health. (Lond. Engl) (2006) [Pubmed]
  4. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. Nabholtz, J.M. Oncology (2006) [Pubmed]
  5. Cardiovascular safety profiles of aromatase inhibitors : a comparative review. Nabholtz, J.M., Gligorov, J. Drug. Saf (2006) [Pubmed]
  6. The role of taxanes in the treatment of breast cancer. Nabholtz, J.M., Gligorov, J. Expert. Opin. Pharmacother (2005) [Pubmed]
  7. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Nabholtz, J.M., Gligorov, J. Expert. Opin. Pharmacother (2005) [Pubmed]
  8. Docetaxel in the treatment of breast cancer: current experience and future prospects. Nabholtz, J.M., Gligorov, J. Expert. Rev. Anticancer. Ther (2005) [Pubmed]
  9. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. Nabholtz, J.M., Falkson, C., Campos, D., Szanto, J., Martin, M., Chan, S., Pienkowski, T., Zaluski, J., Pinter, T., Krzakowski, M., Vorobiof, D., Leonard, R., Kennedy, I., Azli, N., Murawsky, M., Riva, A., Pouillart, P. J. Clin. Oncol. (2003) [Pubmed]
  10. Docetaxel-anthracycline combinations in metastatic breast cancer. Nabholtz, J.M. Breast Cancer Res. Treat. (2003) [Pubmed]
  11. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Nabholtz, J.M., Bonneterre, J., Buzdar, A., Robertson, J.F., Thürlimann, B. Eur. J. Cancer (2003) [Pubmed]
  12. Advances in the use of taxanes in the adjuvant therapy of breast cancer. Nabholtz, J.M., Vannetzel, J.M., Llory, J.F., Bouffette, P. Clin. Breast Cancer (2003) [Pubmed]
  13. Advanced breast cancer updates on anastrozole versus tamoxifen. Nabholtz, J.M. J. Steroid Biochem. Mol. Biol. (2003) [Pubmed]
WikiGenes - Universities